TrialJournal of hematology & oncology2017

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.

Srdan Verstovsek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.